Abstract
miR Sentinel™ Prostate Cancer Test (Sentinel) is a small non-coding RNA-based, non-invasive urine test designed to detect and risk-classify prostate cancer (PCa) with predictive accuracy over 90%. Current care for men suspected for PCa with prostate-specific antigen (PSA)>3ng/mL involves transrectal ultrasound-guided biopsy (TRUSB) with/without magnetic resonance imaging (MRI). Due to poor PSA accuracy, unnecessary biopsies are performed leading to increased costs and biopsy-related complications. MRI further increases costs, access to equipment is limited, and performance varies. This analysis assessed the clincial and budget effects of using Sentinel in biopsy-naïve men 45 and older with elevated PSA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
